Using light, sound, and touch to improve movement and thinking in Parkinson's disease
Official title: Acute Treatment of Parkinson's Disease With Gamma Frequency Stimulation
Run by Massachusetts Institute of Technology · NCT05268887 · Data updated 2026-11-12
This study is testing a new method using light, sound, and touch to see if it can help people with mild Parkinson's disease move better and think more clearly.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 90 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Massachusetts Institute of Technology Academic / other |
| Locations | 1 site (Cambridge, Massachusetts) |
| Status | Recruiting |
| Started | February 9, 2022 |
| Main results expected | November 1, 2027 |
| Study ends | November 2027 |
| Registry record updated | March 31, 2026 |
| Trial ID | NCT05268887 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 45 to 90 with mild idiopathic Parkinson's disease who have stable symptoms and cognitive function.
✕Probably not a fit
Patients with advanced Parkinson's disease or those with significant cognitive impairment may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates a non-invasive method called Gamma Entrainment Using Sensory Stimulation (GENUS) to enhance brain activity in patients with mild Parkinson's disease. By applying light, sound, and tactile stimulation, the researchers aim to boost gamma oscillations in the brain, which may alleviate motor symptoms such as tremors and slowness of movement. The study will involve 40 participants who will undergo electroencephalogram (EEG) assessments before, during, and after stimulation to evaluate the safety and effectiveness of this approach. The goal is to determine if GENUS can serve as a viable therapy for improving motor and cognitive functions in Parkinson's patients.
Why it matters
Potential benefit: If successful, this approach could provide a new non-invasive treatment option to improve motor and cognitive deficits in patients with Parkinson's disease.
How similar studies have gone: Previous studies have shown that similar non-invasive stimulation methods can be effective in other populations, suggesting potential for success in this novel application for Parkinson's disease.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist * Subject is Hoehn \& Yahr stage 2 to 3 * Subject has a Montreal Cognitive Assessment (MOCA) score ≥26. * Subject is \> 45 and \<90 years of age. * proficient in speaking, reading, and understanding English * capable of providing informed written consent * Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required. * Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions Exclusion criteria: * Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia) * history of any psychiatric illness that would pose a safety risk * diagnosis of dementia or other neurological conditions * currently taking sedative medications that are clinically contraindicated * has undergone recent change (\<1 month) in medication * recent drug or alcohol abuse or dependence * laboratory results the would pose safety risk * concurrently or has participated in other clinical trial investigation within 3 months * pregnant * no healthcare * history of epilepsy, stroke, or seizure in past 24 months * diagnosis of migraines * have certain implantable medical devices * contraindications for MRI * life expectancy of less than 2 years
Where it's running
-
Massachusetts Institute of Technology
Cambridge, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Li-Huei Tsai, PhD — Massachusetts Institute of Technology
- Study coordinator: gamma wave
- Email: gamma.wave@mit.edu
- Phone: 617-258-7723
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Tributyrin for PSP: a virtual, early-phase study
This study tests whether tributyrin is safe and tolerable in people with Progressive Supranuclear Palsy who are 45 or older, using virtual visits.
-
A look at why Lewy body conditions cause visual hallucinations
This study tests brain‑imaging in people with Lewy body diseases who do or don’t experience visual hallucinations, and in healthy volunteers, to see how brain networks might create these images.
-
How physical activity might help people with Parkinson’s disease who have DBS-STN implants
This study tests whether adding regular physical activity can help people with Parkinson’s who have DBS-STN stimulation by trying a structured physiotherapy approach alongside standard care.
-
Can hippotherapy improve mobility, gait, balance, and quality of life in people with Parkinson's disease?
This pilot trial tests whether adding horse-assisted therapy to standard rehab helps mobility, gait, balance, and perceived health in adults with Parkinson's disease.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.